TODD STRATEGY GROUP

Lobbying for GILEAD SCIENCES, INC. · American biotechnology company that researches, develops and commercializes drugs.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $80,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Health Issues

Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.